Published on LinkedIn on Dec 1st, 2025
In the global race for medical innovation, market size matters, but market access matters more.
Today, a medical device manufacturer targeting the Gulf Cooperation Council (GCC) faces a paradoxical reality. They (we!) see a wealthy, integrated economic bloc of 60+ million people with world-class healthcare infrastructure. Yet, when they attempt to enter this market, they do not find a single bloc. They find six distinct regulatory fortresses, each requiring separate dossiers, fees, and local representatives.
The result is a “fragmentation tax” that delays patient access to life-saving technologies by years, inflates healthcare costs, and undermines the very precision medicine ambitions enshrined in Qatar’s National Vision 2030, Saudi Arabia’s Vision 2030, and the UAE’s National Genomic Strategy. The solution in my opinion is evident, proven, and overdue: The GCC must move beyond loose harmonization guidelines and establish a legally binding Mutual Recognition System, a “Gulf CE Mark” that grants single-point access to the entire region.
A House With Six Locked Rooms
Currently, the GCC operates on a “Reference and Repeat” model. A manufacturer typically obtains approval from the Saudi Food and Drug Authority (SFDA),the region’s most rigorous regulator, and then must “repeat” the administrative process in the UAE, Kuwait, Bahrain, Oman, and Qatar.
This friction is particularly damaging for Precision Medicine technologies, which are central to the National Visions of Qatar, KSA, and the UAE:
High-Complexity In Vitro Diagnostics (IVDs): Consider a startup with a novel liquid biopsy for early cancer detection, exactly the type of technology Qatar Precision Health Institute’s 40,000+ genome database and Qatar Biobank were designed to validate. To enter the region, they must validate their analytical performance for the SFDA (KSA), then re-submit largely the same technical file to the MOHAP (UAE) or NHRA (Bahrain). The scientific questions are identical. The bureaucratic hurdles are duplicative.
Software as a Medical Device (SaMD): An AI algorithm that detects diabetic retinopathy from retinal scans, critical for the region given GCC diabetes prevalence exceeding 20%, faces an even harder challenge. Software updates happen monthly. If an update requires re-notification in six different countries, the compliance cost often exceeds the revenue potential. The result of this is that the Gulf gets “Version 1.0” while the US and EU get “Version 4.0.”
For the agile biotech startups the region is desperate to attract, this is not an inconvenience. It is a barrier to entry. They simply bypass the GCC in favor of the unified markets of the US or Europe.
The Proposal: A “Gulf Medical Device Passport”
The GCC does not need to build a massive new supranational bureaucracy. It can adopt a Federated Mutual Recognition model, similar to the European Union’s “CE Mark” principle but streamlined for the Gulf’s specific needs.
How it would work:
- Unified Standards: The Gulf Health Council (GHC) elevates existing guidelines to binding “Gulf Regulations,” ensuring all states demand the same technical file structure (IMDRF/GHTF standards).
- Designated Reference Regulators: The bloc formally designates mature regulators (e.g., SFDA and UAE’s EDE) as “Reference Authorities.”
- The Passport Effect: A technical review completed by a Reference Authority is binding. If the SFDA approves a genetic sequencing platform, that approval automatically generates a valid import license for Oman and Kuwait within 30 days, without re-submission.
- Sovereign Safeguards: Member states retain the right to block products only on specific grounds (public health emergencies or specific national ethical concerns), but not for technical re-adjudication.
What the GCC Gains: The Strategic ROI
Harmonization is often sold as an administrative convenience. I believe that for the GCC it is much more: an economic and strategic imperative.
1. The “Launch Market” Status
Currently, the GCC is a “Tier 3” market: innovators launch here only after the US, EU, and Japan. A unified market of 61.2 million high-value patients changes the calculus. It may even create a demand pool large enough to justify “Launch First” strategies, bringing cutting-edge diagnostics and robotics to Gulf patients years earlier than the current timeline.
2. Procurement Power & Cost Reduction
Regulatory fragmentation fractures purchasing power. By harmonizing standards, the GCC can expand its Gulf Joint Procurement programs from pharmaceuticals to complex medical devices. A unified regulatory standard allows the bloc to negotiate bulk pricing for MRI machines or continuous glucose monitors as a single entity, potentially saving billions in healthcare expenditure over the next decade.
3. Regional Specialization (The “Centers of Excellence” Model)
This is the strategic opportunity for smaller states like Qatar. In a harmonized system, not every country needs to be an expert in everything.
- Saudi Arabia could specialize in manufacturing and hardware regulation.
- Qatar could become the “Designated Notified Body” for Precision Medicine and Genomics, leveraging its Biobank and Hamad Medical Corporation infrastructure to validate complex IVDs for the whole bloc.
- UAE could specialize in AI and Digital Health software regulation.
Under a mutual recognition treaty, a genetic test validated in Doha would be legally accepted in Riyadh, an AI diagnostic algorithm certified in Dubai would deploy across all six countries without re-approval, and a vaccine manufactured in Jeddah would gain automatic market authorization throughout the bloc, effectively turning national niches into regional assets.
4. Security of Supply
During the COVID-19 pandemic, borders hardened, and supply chains fractured. Countries with fragmented regulatory systems faced redundant approval bottlenecks even for urgent diagnostics like PCR tests. A unified system would have enabled real-time deployment across all six states from a single approval.
A unified regulatory zone ensures that medical supplies can move as frictionlessly as citizens do between GCC states. It builds a “Health Security Shield” that protects the region from global supply chain volatility.
Learning from Europe: A Smarter Harmonization
The GCC has a second-mover advantage. It can copy the EU’s single market success while avoiding its current (many!) failures.
The EU is currently suffering from the implementation of its new Medical Device Regulation (MDR), which has become so bureaucratic that European companies are fleeing to the US. The GCC can adopt the principle of the Single Market (one approval = all countries) without the process of the EU MDR/IVDR. By leaning on “Reliance Models” (accepting US FDA/EU data) combined with local population data validation, the GCC can be faster and more agile than Europe.
The Gateway to MENA
The GCC has already proven it can harmonize complex sectors. The GCC Customs Union and the Gulf Central Committee for Drug Registration (GCC-DR) are living proof. The medical device sector is the next logical frontier.
But the vision need not stop at the Gulf. A harmonized GCC framework would naturally become the “Regulatory Gold Standard” for the wider Middle East and North Africa (MENA). By extending mutual recognition agreements to key partners – Egypt (105M), Morocco (37M), Algeria (44M), Jordan (11M), and other stable MENA markets- the GCC could effectively lead a common market of over 450 million people. This would create the world’s third-largest medical device market by population, after China and the EU.
This creates a clear “GCC First” strategy: build the regulatory engine in the Gulf, prove it works, then export the standards to the wider region. The timing is favorable as the EU struggles with MDR implementation and the US FDA explores alternative pathways, the GCC has a genuine opportunity to establish itself as the world’s most innovation-friendly unified market. By moving from “Neighboring Markets” to a “Single Market,” the GCC can stop importing innovation and start attracting it.
I believe that for a region investing billions in becoming a global biotech hub, a “Gulf CE Mark” is not just a regulatory update, it is the indispensable infrastructure.